It's over. And there is no opposition to this, no opposition to your rights being taken away.
>>43339045Link to article anon
HRT is incredibly dangerous medicine, about time.
They aren’t going to stop HRT because it’s mostly used for cis women.
What a genuine shithole. I am so happy they have no good trade relations anymore and I hope the straight of Hormuz stays closed so they run out of fuel and can't transport food and medicine.
come to brazil gringxsOTC HRT etc
>>43339154Transwomen suffering is important enough to them to the point where if ciswomen also have to suffer, then so be itIt wasn’t long ago when they decided to make cisf athletes pay for their own genital inspection and chromosomal test to compete.
One of the biggest producers of hormone replacement therapy has been censured by regulators for “systemic failures” that jeopardised patient safety.Theramex, the UK producer of HRT drugs Evorel and Intrarosa, was found to have breached fundamental compliance standards including not updating crucial prescribing information – in some cases for several years – and not making it clear that a drug must not be used during pregnancy.The Prescription Medicines Code of Practice Authority (PMCPA), the UK drug industry’s self-regulatory body, issued the public reprimand against Theramex after its own staff blew the whistle over “alarming” compliance issues and incomplete prescribing information for Evorel and Intrarosa that “jeopardise patient safety”.
https://www.theguardian.com/society/2026/apr/22/hrt-provider-censured-by-uk-regulator-for-systemic-failures-that-put-patients-at-risk
>Yes, Theramex will continue to provide Hormone Replacement Therapy (HRT) to the UK. Despite facing regulatory scrutiny and competition investigations, the company has consistently stated that its supply capabilities remain unaffected and that its full range of products, including Evorel patches, remains in stock and available to patients. Recent developments include:>Regulatory Compliance: In April 2026, Theramex was censured by the UK regulator (PMCPA) for systemic failures in prescribing information and compliance, leading the company to withdraw from the self-regulatory framework. However, the company affirmed it would continue operations under MHRA oversight. >Market Competition: In April 2024, the Competition and Markets Authority (CMA) launched a Phase 1 probe into Theramex’s acquisition of European rights to Viatris’ HRT products (Femoston and Duphaston), citing concerns that the deal could reduce choice and increase prices. Theramex maintained that this investigation would not impact its existing HRT supply in the UK.>Supply Continuity: Theramex has worked closely with the UK Department of Health and Social Care to manage stock issues, increasing production capacity to meet demand and ensuring access to alternatives for women affected by shortages of other HRT brands.
it’s incredible that the british care more about trannies than being minorities in their capital city
>>43339235In tne draft guidance for the EqHRC they stated that businesses can discriminate against anyone who *appears* to be transgender, even if they are actually cis, without legal consequences
